Merck & Co.Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Merck & Co.Diversified pharma anchored by Keytruda, vaccines, and animal health. Entered the obesity pill race in December 2024 by licensing Hansoh's oral small-molecule GLP-1 agonist HS-10535 for $112M upfront and up to $1.9B in milestones; that asset is still preclinical. Its clinical-stage metabolic asset is efinopegdutide, a weekly GLP-1/glucagon co-agonist in Phase 2b for MASH.
2021-Q2-2026-Q1
2021-Q2-2026-Q1
1993-2025
$MRK
Entered the obesity pill race in December 2024, licensing Hansoh's oral small-molecule GLP-1 agonist HS-10535 for $112M upfront and up to $1.9B in milestones. Keytruda cash flow funds the entry, but HS-10535 was preclinical at signing and has still not been reported in human trials, so Merck is the least clinically advanced of the large-cap challengers. Its clinical-stage metabolic asset is efinopegdutide, a weekly GLP-1/glucagon co-agonist in Phase 2b for MASH.